Navigation Links
Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
Date:3/24/2009

SUNNYVALE, Calif. March 24 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced details of technology expected to revolutionize the speed of diagnosis of Mycobacterium tuberculosis (TB) and the resistance to common drug treatment for the disease.

The new test technology, developed in partnership with Foundation for Innovative New Diagnostics (FIND) and the University of Medicine and Dentistry of New Jersey (UMDNJ), and funded by the National Institute of Allergy & Infectious Diseases (NIAID), will leverage the power of Cepheid's GeneXpert(R) System to deliver a highly accurate diagnosis of the disease in less than two hours.

According to the World Health Organization (WHO), approximately two billion people are infected with Mycobacterium tuberculosis. Each year approximately nine million people develop active TB and two million people lose their lives to the illness. This equates to one life every 20 seconds.

"One of FIND's main goals is to help to save the millions of lives that are needlessly lost to TB every year," says Giorgio Roscigno, Chief Executive Officer of FIND. "Cepheid's commitment to researching and bringing this test to market has been outstanding, as is their intention to sell Xpert(R) MTB/RIF on a cost for product basis in the developing world, where it is most needed. We are proud to be working with them on this project."

Rapid diagnosis of TB is vital in areas such as sub-Saharan Africa and Southeast Asia due to the close connection between HIV and TB. Sputum microscopy, which often delivers poor sensitivity in patients suffering from tuberculosis, is almost completely ineffective in those who also have HIV co-infection. The weakened immune system of an HIV-positive person is particularly susceptible to inf
'/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2
... MOUNTAINSIDE, N.J., Oct. 16 National Stem,Cell Holding, ... a,provisional patent application for a newly discovered group ... progenitor cell,lines, that may stimulate a variety of ... skins ability to preserve and repair,itself . ...
... Novartis Takes Top Spot, Previously Held by GlaxoSmithKline ... 16 Thomson,Scientific, part of The Thomson Corporation ... of information solutions to the worldwide research and,business ... recent,quarterly review of scientific literature on drugs and ...
... N.Y., Oct. 15 EpiCept Corporation,(Nasdaq and OMX ... Drewe,Senior Director of Lead Discovery, will be presenting ... at the Hotel Del Coronado in San Diego, ... the advances into pre-clinical,testing of drug discovery efforts ...
Cached Biology Technology:National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications 2National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications 3Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 2EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 3EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 4EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 5
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the "International Biometrics Technology Market - Industry Analysis ... report to their offering. ... attacks and crimes has created a need for high ... methods used for personnel authentication such as username and ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... Biochemistry demonstrates that grapes are able to reduce heart ... increasing the activity of several genes responsible for antioxidant ... known natural source of antioxidants and other polyphenols, which ... observed with grape consumption. This study, funded by ...
... Brussels-BE, 2 May 2013 -- A new analysis has ... which women with oestrogen-receptor positive breast cancer are at ... and may benefit from prolonged endocrine treatment. The ... with oestrogen-receptor positive breast cancer whose cancer recurs more ...
... A Boston University School of Medicine (BUSM) study ... increase their self-compassion and ability to manage thoughts and ... Education Online , also discusses how this innovative course ... more empowered to use mind-body skills with their patients. ...
Cached Biology News:Study uncovers mechanism for how grapes reduce heart failure associated with hypertension 2Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer 2Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer 3BUSM study shows positive impact of mind-body course on well-being of medical students 2
... to Ki67 - Proliferation Marker, prediluted ... related nuclear protein, expressed by proliferating cells ... cycle (G1, S, G2 and M phase). ... Ki67 antibodies are useful in establishing the ...
Request Info...
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Biology Products: